Notwithstanding encouraging clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant opposition from pharmacy benefit managers. These https://jemimassty757505.59bloggers.com/42370216/company-s-drug-faces-is-meeting-pharmacy-benefit-manager-challenges-the-review-at-reimbursement-battles